These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28820582)

  • 1. Pathogenic Mutations Induce Partial Structural Changes in the Native β-Sheet Structure of Transthyretin and Accelerate Aggregation.
    Lim KH; Dasari AKR; Ma R; Hung I; Gan Z; Kelly JW; Fitzgerald MC
    Biochemistry; 2017 Sep; 56(36):4808-4818. PubMed ID: 28820582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solid-State NMR Studies Reveal Native-like β-Sheet Structures in Transthyretin Amyloid.
    Lim KH; Dasari AK; Hung I; Gan Z; Kelly JW; Wright PE; Wemmer DE
    Biochemistry; 2016 Sep; 55(37):5272-8. PubMed ID: 27589034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.
    Rodrigues JR; Simões CJ; Silva CG; Brito RM
    Protein Sci; 2010 Feb; 19(2):202-19. PubMed ID: 19937650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
    Lashuel HA; Lai Z; Kelly JW
    Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NMR Measurements Reveal the Structural Basis of Transthyretin Destabilization by Pathogenic Mutations.
    Leach BI; Zhang X; Kelly JW; Dyson HJ; Wright PE
    Biochemistry; 2018 Jul; 57(30):4421-4430. PubMed ID: 29972637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two distinct aggregation pathways in transthyretin misfolding and amyloid formation.
    Dasari AKR; Hung I; Gan Z; Lim KH
    Biochim Biophys Acta Proteins Proteom; 2019 Mar; 1867(3):344-349. PubMed ID: 30366153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial conformational changes of human transthyretin under partially denaturing conditions.
    Yang M; Lei M; Bruschweiler R; Huo S
    Biophys J; 2005 Jul; 89(1):433-43. PubMed ID: 15821170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why is Leu55-->Pro55 transthyretin variant the most amyloidogenic: insights from molecular dynamics simulations of transthyretin monomers.
    Yang M; Lei M; Huo S
    Protein Sci; 2003 Jun; 12(6):1222-31. PubMed ID: 12761393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease.
    Ferrão-Gonzales AD; Palmieri L; Valory M; Silva JL; Lashuel H; Kelly JW; Foguel D
    J Mol Biol; 2003 May; 328(4):963-74. PubMed ID: 12729768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sequence-dependent unfolding pathway plays a critical role in the amyloidogenicity of transthyretin.
    Yang M; Yordanov B; Levy Y; Brüschweiler R; Huo S
    Biochemistry; 2006 Oct; 45(39):11992-2002. PubMed ID: 17002298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retention of misfolded mutant transthyretin by the chaperone BiP/GRP78 mitigates amyloidogenesis.
    Sörgjerd K; Ghafouri B; Jonsson BH; Kelly JW; Blond SY; Hammarström P
    J Mol Biol; 2006 Feb; 356(2):469-82. PubMed ID: 16376939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transthyretin Aggregation Pathway toward the Formation of Distinct Cytotoxic Oligomers.
    Dasari AKR; Hughes RM; Wi S; Hung I; Gan Z; Kelly JW; Lim KH
    Sci Rep; 2019 Jan; 9(1):33. PubMed ID: 30631096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.
    Hurshman Babbes AR; Powers ET; Kelly JW
    Biochemistry; 2008 Jul; 47(26):6969-84. PubMed ID: 18537267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Changes Associated with Transthyretin Misfolding and Amyloid Formation Revealed by Solution and Solid-State NMR.
    Lim KH; Dasari AK; Hung I; Gan Z; Kelly JW; Wemmer DE
    Biochemistry; 2016 Apr; 55(13):1941-4. PubMed ID: 26998642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidation inhibits amyloid fibril formation of transthyretin.
    Maleknia SD; Reixach N; Buxbaum JN
    FEBS J; 2006 Dec; 273(23):5400-6. PubMed ID: 17116243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution.
    Quintas A; Saraiva MJ; Brito RM
    FEBS Lett; 1997 Dec; 418(3):297-300. PubMed ID: 9428731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
    Lai Z; Colón W; Kelly JW
    Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrinsic versus mutation dependent instability/flexibility: a comparative analysis of the structure and dynamics of wild-type transthyretin and its pathogenic variants.
    Lei M; Yang M; Huo S
    J Struct Biol; 2004 Nov; 148(2):153-68. PubMed ID: 15477096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
    Lashuel HA; Wurth C; Woo L; Kelly JW
    Biochemistry; 1999 Oct; 38(41):13560-73. PubMed ID: 10521263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Localized structural fluctuations promote amyloidogenic conformations in transthyretin.
    Lim KH; Dyson HJ; Kelly JW; Wright PE
    J Mol Biol; 2013 Mar; 425(6):977-88. PubMed ID: 23318953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.